EE9900328A - Tiasooli benseensulfoonamiidid ß3-agonistidena diabeedi ja rasvumuse ravis - Google Patents
Tiasooli benseensulfoonamiidid ß3-agonistidena diabeedi ja rasvumuse ravisInfo
- Publication number
- EE9900328A EE9900328A EEP199900328A EEP9900328A EE9900328A EE 9900328 A EE9900328 A EE 9900328A EE P199900328 A EEP199900328 A EE P199900328A EE P9900328 A EEP9900328 A EE P9900328A EE 9900328 A EE9900328 A EE 9900328A
- Authority
- EE
- Estonia
- Prior art keywords
- obesity
- agonists
- diabetes
- treatment
- benzenesulfonamides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3676097P | 1997-01-28 | 1997-01-28 | |
| GBGB9705041.3A GB9705041D0 (en) | 1997-03-12 | 1997-03-12 | Thiazole benzenesulfonamides as selective B3 agonists for the treatment of diabetes and obesity |
| PCT/US1998/001317 WO1998032753A1 (en) | 1997-01-28 | 1998-01-23 | THIAZOLE BENZENESULFONAMIDES AS β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE9900328A true EE9900328A (et) | 2000-02-15 |
Family
ID=26311166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP199900328A EE9900328A (et) | 1997-01-28 | 1998-01-23 | Tiasooli benseensulfoonamiidid ß3-agonistidena diabeedi ja rasvumuse ravis |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0968209A1 (et) |
| JP (1) | JP2001509166A (et) |
| KR (1) | KR20000070568A (et) |
| CN (1) | CN1251099A (et) |
| AR (1) | AR011092A1 (et) |
| AU (1) | AU728812B2 (et) |
| BG (1) | BG103686A (et) |
| BR (1) | BR9807096A (et) |
| CA (1) | CA2278739A1 (et) |
| EA (1) | EA199900692A1 (et) |
| EE (1) | EE9900328A (et) |
| HR (1) | HRP980044A2 (et) |
| HU (1) | HUP0002053A3 (et) |
| ID (1) | ID22273A (et) |
| IL (1) | IL131130A0 (et) |
| IS (1) | IS5131A (et) |
| NO (1) | NO993646L (et) |
| PE (1) | PE52299A1 (et) |
| PL (1) | PL334833A1 (et) |
| SK (1) | SK100099A3 (et) |
| TR (1) | TR199902442T2 (et) |
| WO (1) | WO1998032753A1 (et) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19824175A1 (de) * | 1998-05-29 | 1999-12-02 | Novartis Ag | Amino-azol-Verbindungen |
| ATE385421T1 (de) | 2000-01-21 | 2008-02-15 | Novartis Pharma Gmbh | Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica |
| EP1258253A1 (en) * | 2000-01-28 | 2002-11-20 | Asahi Kasei Kabushiki Kaisha | Novel remedies with the use of beta3 agonist |
| DK1138685T3 (da) | 2000-03-31 | 2004-08-09 | Pfizer Prod Inc | Fremgangsmåde til fremstilling af substituerede pyridiner |
| CZ2003106A3 (cs) | 2000-07-13 | 2003-04-16 | Eli Lilly And Company | Agonisté adrenergního beta-3 receptoru |
| US6498170B2 (en) * | 2000-07-17 | 2002-12-24 | Wyeth | Cyclamine sulfonamides as β-3 adrenergic receptor agonists |
| US6537994B2 (en) | 2000-07-17 | 2003-03-25 | Wyeth | Heterocyclic β3 adrenergic receptor agonists |
| US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| US6465501B2 (en) | 2000-07-17 | 2002-10-15 | Wyeth | Azolidines as β3 adrenergic receptor agonists |
| US6410734B1 (en) | 2000-07-17 | 2002-06-25 | Wyeth | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists |
| US6369232B1 (en) * | 2000-08-15 | 2002-04-09 | Hoffmann-La Roche Inc. | Tetrazolyl-phenyl acetamide glucokinase activators |
| DE60120748T2 (de) | 2000-11-10 | 2007-05-16 | Eli Lilly And Co., Indianapolis | 3-substituierte oxindolderivate als beta-3-agonisten |
| CA2431171A1 (en) | 2000-12-08 | 2002-06-13 | Takeda Chemical Industries, Ltd. | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof |
| AR035605A1 (es) | 2000-12-11 | 2004-06-16 | Bayer Corp | Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores |
| AR035858A1 (es) | 2001-04-23 | 2004-07-21 | Bayer Corp | Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3 |
| DE60208792T2 (de) * | 2001-06-22 | 2006-08-31 | Merck & Co., Inc. | Tyrosin-kinase inhibitoren |
| JP2005507872A (ja) | 2001-08-14 | 2005-03-24 | イーライ・リリー・アンド・カンパニー | ３−置換オキシインドールβ３アゴニスト |
| DE60215028T2 (de) | 2001-08-14 | 2007-03-15 | Eli Lilly And Co., Indianapolis | Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes |
| DE60208815T2 (de) * | 2001-10-12 | 2006-07-20 | Bayer Pharmaceuticals Corp., West Haven | Phenyl substituierte 5-gliedrige stickstoff enthaltende heterocyclen zur behandlung von fettleibigkeit |
| ES2242890T3 (es) | 2001-11-20 | 2005-11-16 | Eli Lilly And Company | Agonistas beta 3 de oxindol 3-sustituido. |
| WO2003044017A1 (en) | 2001-11-20 | 2003-05-30 | Eli Lilly And Company | Beta 3 adrenergic agonists |
| US7009060B2 (en) | 2002-01-11 | 2006-03-07 | Eli Lilly And Company | 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists |
| US6872724B2 (en) | 2002-07-24 | 2005-03-29 | Merck & Co., Inc. | Polymorphs with tyrosine kinase activity |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
| WO2006132196A1 (ja) * | 2005-06-08 | 2006-12-14 | Asahi Kasei Pharma Corporation | β３作動薬を含有する新規な医薬 |
| CN102908350B (zh) | 2005-09-14 | 2014-07-23 | 武田药品工业株式会社 | 用于治疗糖尿病的二肽基肽酶抑制剂 |
| BRPI0616463A2 (pt) | 2005-09-29 | 2011-06-21 | Merck & Co Inc | composto, composição farmacêutica, e, uso de um composto |
| EP1937264B1 (en) | 2005-10-04 | 2011-06-08 | Merck Sharp & Dohme Corp. | Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence |
| EP2946778A1 (en) | 2006-09-22 | 2015-11-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Ｍｓｄ株式会社 | インドールジオン誘導体 |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| JP5546451B2 (ja) | 2007-06-04 | 2014-07-09 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト |
| AU2009256157B2 (en) | 2008-06-04 | 2014-12-18 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| WO2010009319A2 (en) | 2008-07-16 | 2010-01-21 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| JP5557845B2 (ja) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体 |
| WO2011041293A1 (en) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
| PT2531501E (pt) | 2010-02-03 | 2014-02-17 | Takeda Pharmaceutical | Inibidores da cinase de regulação do sinal de apoptose 1 |
| EP2538784B1 (en) | 2010-02-25 | 2015-09-09 | Merck Sharp & Dohme Corp. | Benzimidazole derivatives useful anti-diabetic agents |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| EP2677869B1 (en) | 2011-02-25 | 2017-11-08 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| RU2015106909A (ru) | 2012-08-02 | 2016-09-27 | Мерк Шарп И Доум Корп. | Антидиабетические трициклические соединения |
| ES2394349B1 (es) | 2012-08-29 | 2013-11-04 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar |
| WO2014108449A1 (en) | 2013-01-08 | 2014-07-17 | Atrogi Ab | A screening method, a kit, a method of treatment and a compound for use in a method of treatment |
| CA2898482A1 (en) | 2013-02-22 | 2014-08-28 | Linda L. Brockunier | Antidiabetic bicyclic compounds |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| US10011637B2 (en) | 2013-06-05 | 2018-07-03 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | ANTIDIABETIC HETEROCYCLIC COMPOUNDS |
| EP3558298A4 (en) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | ANTIDIABETIC SPIROCHROMAN COMPOUNDS |
| GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714736D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714740D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714745D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0091749A3 (en) * | 1982-04-08 | 1984-12-05 | Beecham Group Plc | Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them |
| US5451677A (en) * | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| IL113410A (en) * | 1994-04-26 | 1999-11-30 | Merck & Co Inc | Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them |
-
1998
- 1998-01-23 EP EP98903677A patent/EP0968209A1/en not_active Withdrawn
- 1998-01-23 KR KR1019997006814A patent/KR20000070568A/ko not_active Application Discontinuation
- 1998-01-23 HU HU0002053A patent/HUP0002053A3/hu unknown
- 1998-01-23 JP JP53214898A patent/JP2001509166A/ja active Pending
- 1998-01-23 CN CN98803585A patent/CN1251099A/zh active Pending
- 1998-01-23 AU AU60384/98A patent/AU728812B2/en not_active Ceased
- 1998-01-23 TR TR1999/02442T patent/TR199902442T2/xx unknown
- 1998-01-23 PL PL98334833A patent/PL334833A1/xx unknown
- 1998-01-23 CA CA002278739A patent/CA2278739A1/en not_active Abandoned
- 1998-01-23 ID IDW990755A patent/ID22273A/id unknown
- 1998-01-23 EA EA199900692A patent/EA199900692A1/ru unknown
- 1998-01-23 SK SK1000-99A patent/SK100099A3/sk unknown
- 1998-01-23 IL IL13113098A patent/IL131130A0/xx unknown
- 1998-01-23 EE EEP199900328A patent/EE9900328A/et unknown
- 1998-01-23 WO PCT/US1998/001317 patent/WO1998032753A1/en not_active Application Discontinuation
- 1998-01-23 BR BR9807096-7A patent/BR9807096A/pt not_active IP Right Cessation
- 1998-01-27 AR ARP980100357A patent/AR011092A1/es unknown
- 1998-01-28 PE PE1998000064A patent/PE52299A1/es not_active Application Discontinuation
- 1998-01-28 HR HR9705041.3A patent/HRP980044A2/hr not_active Application Discontinuation
-
1999
- 1999-07-23 IS IS5131A patent/IS5131A/is unknown
- 1999-07-27 NO NO993646A patent/NO993646L/no not_active Application Discontinuation
- 1999-08-24 BG BG103686A patent/BG103686A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0002053A2 (hu) | 2001-08-28 |
| WO1998032753A1 (en) | 1998-07-30 |
| AU6038498A (en) | 1998-08-18 |
| NO993646L (no) | 1999-09-27 |
| HRP980044A2 (en) | 1998-10-31 |
| PL334833A1 (en) | 2000-03-27 |
| EA199900692A1 (ru) | 2000-02-28 |
| TR199902442T2 (xx) | 2000-07-21 |
| SK100099A3 (en) | 2000-05-16 |
| AR011092A1 (es) | 2000-08-02 |
| BR9807096A (pt) | 2000-04-18 |
| CN1251099A (zh) | 2000-04-19 |
| ID22273A (id) | 1999-09-23 |
| IL131130A0 (en) | 2001-01-28 |
| EP0968209A1 (en) | 2000-01-05 |
| IS5131A (is) | 1999-07-23 |
| NO993646D0 (no) | 1999-07-27 |
| HUP0002053A3 (en) | 2001-09-28 |
| KR20000070568A (ko) | 2000-11-25 |
| CA2278739A1 (en) | 1998-07-30 |
| JP2001509166A (ja) | 2001-07-10 |
| PE52299A1 (es) | 1999-05-26 |
| AU728812B2 (en) | 2001-01-18 |
| BG103686A (bg) | 2000-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE9900328A (et) | Tiasooli benseensulfoonamiidid ß3-agonistidena diabeedi ja rasvumuse ravis | |
| AP9901719A0 (en) | Treatment of diabetes with thiazolidinedione and metormin | |
| ID29298A (id) | Metode dan komposisi untuk mengobati apnea selama tidur | |
| FI970357A (fi) | Tyypin II diabeteksen hoitoon käyttökelpoisia bensoksatsoli- ja pyridiinijohdannaisia | |
| HUP0203367A3 (en) | Benzylidine-thiazolidinediones and analogues and their use in the treatment of diabetes | |
| DE69836008D1 (de) | Zusammensetzung und behandlungsmittel | |
| IL128894A0 (en) | Materials and methods relating to the diagnosis and treatment of diabetes and obesity | |
| PT1017408E (pt) | Utilizacao de tetra-hidrolipstatina no tratamento de diabetes de tipo ii | |
| FI980246A0 (fi) | Menetelmä keittimen käyttämiseksi ja keitin | |
| ZA98647B (en) | Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity | |
| FI103463B1 (fi) | Tietokone ja menetelmä tietokoneen käyttämiseksi | |
| NO984836D0 (no) | Substituerte benzylaminer og deres anvendelse for behandling av depresjon | |
| EE04263B1 (et) | Farmatseutiline kompositsioon piperidinoalkanoolantihistamiini ja selle derivaatide biosaadavuse suurendamiseks ning allergiliste reaktsioonide raviks patsiendil | |
| DE69528571T2 (de) | Füllen von löchern und dergleichen in substraten | |
| ID24065A (id) | Pengobatan diabetes dengan tiozolidindinon dan sulfonilurea | |
| NO20000229L (no) | Behandling av diabetes med tiazolidindion og sulfonylurea | |
| PL337577A1 (en) | Treatment of diabetes with thiazolydinone and alpha - glucosidaze inhibitor | |
| GB9705041D0 (en) | Thiazole benzenesulfonamides as selective B3 agonists for the treatment of diabetes and obesity | |
| GB9700667D0 (en) | Materials and methods relating to the treatment of biofilms | |
| UA25095A (uk) | Ліhімеhт для лікуваhhя каhдидозhого і змішаhого вульвовагіhіту | |
| GB9711042D0 (en) | Combination therapy for the treatment of diabetes and obesity | |
| HUP0002669A3 (en) | Treatment of diabetes with thiazolidinedione and sulphonylurea | |
| PL337220A1 (en) | Application of leptin antagonists in treating diabetes |